Grant: Operating Grant
McMaster University
$710,845.00
Unraveling the immune mechanisms of delayed onset of T cell immunity against pulmonary tuberculosis
FY 2012-13
Summary
Tuberculosis (TB) is a chronic lung infectious disease which has been haunting humankind for thousands of years. One third of world population is latently infected. Every year 9 million people develop TB disease and about 2 million people die. Young children are particularly prone to TB. BCG is the only TB vaccine which has been used for 90 years but it has failed to effectively control TB in the lung. One unique phenomenon that scientists have noticed is that anti-TB immunity develops in a much slower pace after infection in the lung than the immunity against other types of lung infection. It is believed that this represents one important reason for the failure of BCG to protect the lung. Our current project sets out to decipher the mechanisms behind the mysterious sluggish immune responses to TB infection. Enhanced knowledge will help us design the new immune strategies to enhance lung protection in BCG-vaccinated young children.
Department
Program
Operating Grant
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
266062
Name
Xing Zhou
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Respiratory System
Projecttitle
Unraveling the immune mechanisms of delayed onset of T cell immunity against pulmonary tuberculosis
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$710,845
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Destructive Lung Disease; Immune Regulation; Lung Inflammation; Lung Mucosal Immunity; Pulmonary Tuberculosis; T Cell Responses
Abstract
Tuberculosis (TB) is a chronic lung infectious disease which has been haunting humankind for thousands of years. One third of world population is latently infected. Every year 9 million people develop TB disease and about 2 million people die. Young children are particularly prone to TB. BCG is the only TB vaccine which has been used for 90 years but it has failed to effectively control TB in the lung. One unique phenomenon that scientists have noticed is that anti-TB immunity develops in a much slower pace after infection in the lung than the immunity against other types of lung infection. It is believed that this represents one important reason for the failure of BCG to protect the lung. Our current project sets out to decipher the mechanisms behind the mysterious sluggish immune responses to TB infection. Enhanced knowledge will help us design the new immune strategies to enhance lung protection in BCG-vaccinated young children.
Competitiondate
201209
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Xing, Zhou
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $710,845~ $0~
